RxDoctor Payments Data

Chandni Bheeman

Endocrinology, Diabetes & Metabolism · Hackensack, NJNPI 1881156602

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 51 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$256
  • Amgen$173
  • Medtronic$83
  • Sanofi-aventis U.S. LLC$72
  • Corcept Therapeutics$64
  • Lilly USA, LLC$55
  • plus $336 from 12 others

What the payments were for

  • Food & beverage$1,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 35th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$8,629
Medicare patients
34
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$50,771
JardianceEmpagliflozin37$31,692
TrulicityDulaglutide13$15,616
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$7,941
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,076
Eplerenone13$959
Metformin Hcl ErMetformin Hcl17$291
Methimazole21$208
Levothyroxine Sodium17$179
Metformin Hcl16$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$256$50,77142 claims
Boehringer IngelheimJardiance$17$31,69237 claims
Lilly USA, LLCTrulicity$55$15,61613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →